← FDA DRUG APPROVALS

FDA ANDA · ANDA076159

GLIPIZIDE

Sponsor: PH HEALTH

APPLICATION
ANDA076159
TYPE
ANDA
ORIGINAL APPROVAL
2013-09-20
LATEST ACTION
2020-04-14
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

GLIPIZIDEDiscontinued
GLIPIZIDE 5MG · TABLET, EXTENDED RELEASE · ORAL
GLIPIZIDEDiscontinued
GLIPIZIDE 10MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2020-04-14Labeling · Supplement 6 · standardAP
2020-04-14Labeling · Supplement 7 · standardAP
2020-04-14Labeling · Supplement 10 · standardAP
2013-09-20OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →